The size of the Genetic Testing Market in the Middle East & Africa was worth USD 3.68 billion in 2021 and is estimated to reach USD 5.07 billion by 2026, growing at a CAGR of 6.64% during the forecast period.
The rise in the prevalence of genetic disorders and cancer has had a favorable impact on the growth of genetic testing in the MEA region. During the forecast period, personalized medicine therapy is expected to boost the market growth. As the demand for quick, cost-effective, and accurate tests grows, several firms consider giving actionable recommendations alongside the test findings. Customers are more likely to seek out customized services due to this technique, which boosts customer satisfaction. In addition, direct-to-consumer laboratory testing, also known as direct access testing, allows patients to order tests from a lab without going through a healthcare provider.
Genetic testing has been widely used in pharmacogenomics, often known as drug-gene testing. Furthermore, genetic testing methodologies are projected to enhance market growth throughout the forecast period. These test findings can be used to monitor a current health condition, diagnose an undetected medical issue, or provide information on personal health characteristics.
Additionally, factors such as technological advancements in the field of genetic testing, as well as the rising risk of chromosomal abnormalities as maternal age rises, are further estimated to accelerate the growth rate of the market. In addition, the growing incidence of male and female infertility is also forecasted to contribute to the market’s growth.
During the forecast period, however, standardized debates about genetic test-based diagnostics and tight legal requirements for product approvals are projected to hamper the growth of the genetic testing market in the MEA region.
This research report on the MEA genetic testing market has been segmented and sub-segmented into the following categories.
By Application:
By Test:
By Country:
Geographically, the MEA is projected to account for a moderate share in the global genetic testing market in 2020. However, the market in this region is forecasted to register a steady growth rate during the forecast period. Due to increased demand for direct-to-consumer genetic testing and rising consumer interest in personalized medications, MEA has a moderate share of worldwide markets. In addition, the genetic testing market in this region is growing due to increased affordability, rising healthcare spending, and increased awareness of genetic illnesses early detection.
Countries such as UAE and Kuwait are increasing their healthcare capital equipment expenditures, the installed base of various types of products for the genetic testing market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios, all of which affect the genetic testing market.
When present in two copies, individuals with a copy of a gene mutation that causes a hereditary ailment is detected through genetic testing in the research. This type of test is accessible for those who have a family history of genetic disorders and people who are at a higher risk of certain genetic illnesses because of their ethnicity. In addition, if both parents are tested, the test can reveal information regarding the risk of a child developing a genetic condition.
The market for genetic testing in the Middle East and Africa is predicted to rise significantly in the future, owing to an increase in the occurrence of genetic illnesses and cancer and a growing population as more excellent knowledge and adoption of personalized therapies.
KEY MARKET PLAYERS:
Companies that are playing a significant role in the MEA Genetic Testing Market profiled in this report are Abbott Laboratories, Roche Molecular Diagnostics Inc., Abbott Molecular Inc., AutoGenomics Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Quest Diagnostics Inc., Transgenomic Inc., and Applied Biosystems Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Prenatal Testing
5.1.4 Neonatal Testing
5.2 By Application
5.2.1 Cancer Testing
5.2.2 Prenatal Testing
5.2.3 Pharmacogenomics Testing
5.2.4 Presdisposition Testing
6. Geographical Analysis
6.1 Introduction
6.2 Middle East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Roche Molecular Diagnostics Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Abbott Laboratories
8.3 AutoGenomics Inc.
8.4 Celera Group
8.5 ELITech Group
8.6 BioRad Laboratories
8.7 Quest Diagnostics Inc
8.8 Transgenomic Inc.
8.9 Applied Biosystems Inc.,
8.10 PerkinElmer Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
